Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS) in patients with resected stage III colon cancer receiving cetuximab (Cmab): Results from NCCTG N0147.
- Citation:
- J Clin Oncol vol 29 (15s) abstr 3607
- Meeting Instance:
- ASCO 2011
- Year:
- 2011
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Program:
- TRP
- Primary Committee:
- Correl Sci NOS
- Sec. Committees:
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- S. R. Alberts S. N. Thibodeau D. J. Sargent M. R. Mahoney F. Sinicrope A. F. Shields E. Chan R. M. Goldberg S. Gill M. S. Kahlenberg J. T. Quesenberry T. C. Smyrk A. Grothey S. G. Nair
- Networks:
- Study
- NCCTG-N0147
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: